Medicine, Hematology Oncology Division

Grants

Grants per year 1995 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2034

• 385 Active
• 1478 Finished

Grants per year

Search results

• Finished

  Prot #213304: Expanded Access Program for Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma Who are Refractory to a Proteasome Inhibitor, and an Immunomodulatory Agent, and an Anti-CD38 Antibody

  Singhal, S.

  Quintiles, Inc., GlaxoSmithKline LLC

  3/11/20 → 3/11/23

  Project: Research project

• Abemaciclib treatment for EBV-associated lymphoma

  Longnecker, R. M. & Ikeda, M.

  Eli Lilly and Company

  3/10/20 → 3/9/22

  Project: Research project

  • Lymphoma 100%
  • Abemaciclib 100%
  • lymphomas 100%
  • Burkitt Lymphoma 50%
  • Membrane Protein 50%

• Prot #CA013-004: A Phase 1/2a Study of BMS-986179 Administered Alone and in Combination with Nivolumab (BMS-936558) in Subjects with Advanced Solid Tumors

  Sosman, J. A.

  Bristol-Myers Squibb Company

  3/10/20 → 3/10/23

  Project: Research project

• Targeting the Oncometabolism with Mitochondria-Directed Chemicals

  Bonini, M.

  Medical College of Wisconsin, Army Research Office

  3/1/20 → 5/16/21

  Project: Research project

  • Mitochondrion 100%
  • mitochondria 100%
  • Glycolysis 50%
  • Breast Cancer 50%
  • Tumor Progression 50%

• Prot #R2810-ONC-1788: A Randomized, Placebo-Controlled, Double-Blind Study of Adjuvant Cemiplimab Versus Placebo after Surgery and Radiation Therapy in Patients with High Risk Cutaneous Squamous Cell Carcinoma (CSCC)

  Chandra, S.

  ICON Clinical Research Limited, Regeneron Pharmaceuticals, Inc.

  2/25/20 → 9/28/21

  Project: Research project

• Prot #68284528MMY2003: A Phase 2, Multicohort Open-Label Study of JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA in Subjects with Multiple Myeloma (CARTITUDE-2)

  Singhal, S.

  Janssen Research & Development, LLC

  2/11/20 → 2/11/23

  Project: Research project

• Prot #B9991040: A Phase 1b/2 Study to Evaluate Safety and Clinical Activity of Avelumab in Combination with Bempegaldesleukin (NKTR-214) with or without Talazoparib or Enzalutamide in Participants with Locally Advanced or Metastatic Solid Tumors

  VanderWeele, D. J.

  Pfizer Inc.

  2/10/20 → 2/10/23

  Project: Research project

• Prot #CA209-8Y8: A Phase 3b, Randomized, Double-blind Study of Nivolumab Combined with Ipilimumab versus Nivolumab Monotherapy for Patients with Previously Untreated Advanced Renal Cell Carcinoma and Intermediate- or Poor-Risk Factors

  Sosman, J. A.

  Bristol-Myers Squibb Company

  2/5/20 → 2/5/23

  Project: Research project

• Prot #KRT-232-104: An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined with Low-Dose Cytarabine (LDAC) or Decitabine in Patients with Acute Myeloid Leukemia (AML)

  Altman, J. K.

  INC Research, LLC, Kartos Therapeutics, Inc.

  2/5/20 → 2/5/23

  Project: Research project

• Targeting Platinum Resistance in Ovarian Cancer

  Matei, D. E.

  Friends of Prentice

  1/28/20 → 8/31/22

  Project: Research project

  • cancer 100%
  • platinum 100%
  • ovaries 100%
  • Platinum 100%
  • Ovary Cancer 100%

• Prot #8951-CL-0301: A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of Zolbetuximab (IMAB362) Plus mFOLFOX6 Compared with Placebo Plus mFOLFOX6 as First-line Treatment of Subjects with Claudin (CLDN) 18.2-Positive, HER2-Negative,

  Mulcahy, M. F.

  Parexel, Astellas Pharma Global Development, Inc.

  1/27/20 → 1/27/23

  Project: Research project

• Prot #A19-11184: Phase I Study of APR-246 in Combination with Venetoclax and Azacitidine in TP53-Mutant Myeloid Malignancies

  Altman, J. K.

  Theradex, Aprea Therapeutics AB

  1/21/20 → 1/21/23

  Project: Research project

• Prot #BTCRC-GI18-149: Phase II Study of the Combination of Abemaciclib and Pembrolizumab in Locally Advanced Unresectable or Metastatic Gastroesophageal Adenocarcinoma: Big Ten Cancer Research Consortium BTCRC-GI18-149

  Benson III, A. B.

  Hoosier Cancer Research Network, Inc., Lilly USA, LLC

  1/21/20 → 1/21/23

  Project: Research project

• Prot #Vedolizumab-3035: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Vedolizumab in the Prophylaxis of Intestinal Acute Graft-Versus-Host Disease in Subjects Undergoing Allogeneic Hematopoietic S

  Moreira, J.

  Pharmaceutical Research Associates, Inc., Millennium Pharmaceuticals, Inc.

  1/17/20 → 1/17/23

  Project: Research project

• Supportive Oncology Collaborative for Adolescents and Young Adults

  Garcia, S. F., Dinner, S. N., Kircher, S. M. & Sanford, S. D.

  Coleman Foundation, Inc.

  1/1/20 → 12/31/22

  Project: Research project

  • Young Adult 100%
  • Oncology 100%
  • patients 100%
  • adolescents 100%
  • adults 100%

• A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study).

  Patel, J. D.

  Hope Foundation

  1/1/20 → 12/31/20

  Project: Research project

  • cancer 100%
  • biological markers 100%
  • immunotherapy 100%
  • cost 100%
  • lungs 100%

• Supportive Oncology Collaborative for Adolescents and Young Adults

  Garcia, S. F., Dinner, S. N., Kircher, S. M. & Sanford, S. D.

  Coleman Foundation, Inc.

  1/1/20 → 12/31/22

  Project: Research project

  • Young Adult 100%
  • Oncology 100%
  • patients 100%
  • adolescents 100%
  • adults 100%

• Prot #D9103C00001: A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Following Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with Unresected Stage I/II Lymph-node Negative

  Mohindra, N. A.

  AstraZeneca Pharmaceuticals LP

  12/20/19 → 12/20/22

  Project: Research project

• Prot #CPI-006-001: A Phase 1/1b Multicenter Study To Evaluate The Humanized Anti-CD73 Antibody, CPI-006, As A Single Agent or In Combination With Ciforadenant, with Pembrolizumab, And With Ciforadenant Plus Pembrolizumab In Adult Subjects With Advanced Ca

  Sosman, J. A.

  Corvus Pharmaceuticals, Inc.

  12/20/19 → 12/20/22

  Project: Research project

• Prot #7465-CL-0108: A Multicenter, Open-label, Expanded Access Treatment Protocol of Enfortumab Vedotin in Subjects with Locally Advanced or Metastatic Urothelial Carcinoma (EV-901)

  Morgans, A. K.

  Parexel, Astellas Pharma Global Development, Inc.

  12/17/19 → 12/17/22

  Project: Research project

• 57148711: Assessing Treatment Patterns of CDK 4/6 Inhibitor Utilization in HR+/HER2- Metastatic Breast within Northwestern Medicine and Addressing Opportunities for Improvement

  Gradishar, W. J.

  Pfizer Inc.

  12/16/19 → 3/31/22

  Project: Research project

• Prot #ALT-002-SRE-01: A Phase I/II Dose Escalation Study of AP-002 In Patients with Advanced or Recurrent Solid Tumors

  Shah, A. N.

  Altum Pharmaceuticals Inc.

  12/9/19 → 12/9/22

  Project: Research project

• Prot #R2810-ONC-1806: Cemiplimab Survivorship Epidemiology (CASE) Study

  Chandra, S.

  inVentiv Health Clinical, Regeneron Pharmaceuticals, Inc.

  12/5/19 → 12/5/22

  Project: Research project

• Prot #M14-239: Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c-Met+ Non-Small Cell Lung Cancer

  Mohindra, N. A.

  AbbVie Inc.

  12/4/19 → 12/4/23

  Project: Research project

• Prot #Ad-p53-002: A Phase 2, Multi-Center, Open Label Study to Evaluate Efficacy and Safety of Adenoviral p53 (Ad-p53) in Combination with Immune Checkpoint Inhibitor Therapy in Patients with Progression or Recurrence of Head and Neck Squamous Cell Carcin

  Boumber, Y.

  MultiVir Inc.

  11/22/19 → 11/22/22

  Project: Research project